Updated

Updated · CBS New York · Jul 25

RenovoCath Trial Keeps 83-Year-Old's Stage III Pancreatic Cancer Stable for 1 Year

Updated

Updated · CBS New York · Jul 25

RenovoCath Trial Keeps 83-Year-Old's Stage III Pancreatic Cancer Stable for 1 Year

1 articles · Updated · CBS New York · Jul 25

Mid-April scans showed Hernando Salcedo’s Stage III pancreatic cancer had remained stable and had not spread, about one year after his 2025 diagnosis.
Salcedo entered the RenovoCath clinical trial after standard chemotherapy left him unable to eat, losing weight and largely bedridden from severe side effects.
The catheter system delivers chemotherapy directly into the artery nearest the tumor, limiting whole-body exposure; prior data cited by his doctor showed 65% fewer adverse effects and a six-month survival gain versus standard chemotherapy.
After four months of every-other-week catheter treatment, Salcedo said nausea and pain largely disappeared, and he regained enough strength to resume walks and travel.
Stage III pancreatic cancer has a 15% five-year survival rate, and final trial data for RenovoCath in this setting is expected in late 2027.

Sources

With new FDA designations in 2026, will targeted arterial delivery finally make surviving pancreatic cancer a reality for everyone?

Could a simple catheter revolutionize how we treat deadly cancers without the toxic side effects of traditional chemotherapy?

If localized chemotherapy can restore a bedridden patient's life, why is whole-body systemic treatment still the standard of care?

1 total